Print

Bayer Biological Products Signs Exclusive Agreement With World Federation of Hemophilia To Fund International Nursing Fellowship Program; Bayer BP Strengthens Its Commitment To The Global Hemophilia Community 
10/19/2005 5:13:04 PM

BERKELEY, Calif.--(BUSINESS WIRE)--April 18, 2005--Bayer Biological Products (BP) announced today the launch of the World Federation of Hemophilia's (WFH) International Hemophilia Nursing Fellowship Program, a new fellowship program providing state-of-the-art hemophilia education and training to nurses in developing countries. The program will extend the benefits of WFH's highly successful International Hemophilia Training Center Fellowship program by providing training opportunities for nurses, critically important members of the hemophilia treatment team. This announcement of the new nursing fellowship program coincides with the 2005 celebration of WFH's World Hemophilia Day on April 17. Consistent with WFH's goal of improving hemophilia care in developing countries, the aim of the WFH International Hemophilia Nursing Fellowship Program is to train nursing professionals from developing countries in the diagnosis and management of hemophilia and related bleeding disorders. Through Bayer BP's exclusive support, the WFH International Hemophilia Nursing Fellowship Program will support three to four nurses annually to travel to one of the 31 WFH-designated International Hemophilia Training Centers (IHTCs) to be paired with a hemophilia nurse to receive clinical and laboratory training.